TR200002480T2 - İzaşemi tedavisi için guanidin türevleri - Google Patents

İzaşemi tedavisi için guanidin türevleri

Info

Publication number
TR200002480T2
TR200002480T2 TR2000/02480T TR200002480T TR200002480T2 TR 200002480 T2 TR200002480 T2 TR 200002480T2 TR 2000/02480 T TR2000/02480 T TR 2000/02480T TR 200002480 T TR200002480 T TR 200002480T TR 200002480 T2 TR200002480 T2 TR 200002480T2
Authority
TR
Turkey
Prior art keywords
izazemi
treatment
nhe
inhibitors
guanidine derivatives
Prior art date
Application number
TR2000/02480T
Other languages
English (en)
Inventor
S. Hamanaka Ernest
Guzman-Perez Angel
B. Ruggeri Roger
T. Wester Ronald
J. Mularski Christian
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of TR200002480T2 publication Critical patent/TR200002480T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Abstract

NHE-1 önleyicileri, bu tür NHE-1 önleyicilerini kullanma metodlari ve tür NHE-1 önleyicilerini içeren farmasötik kompozisyonlar. NHE-1 önleyicileri doku izsemisinden kaynaklanan doku hasarinin azaltilmasi için yararlidir.
TR2000/02480T 1998-02-27 1999-02-05 İzaşemi tedavisi için guanidin türevleri TR200002480T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7636298P 1998-02-27 1998-02-27

Publications (1)

Publication Number Publication Date
TR200002480T2 true TR200002480T2 (tr) 2000-12-21

Family

ID=22131525

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2000/02480T TR200002480T2 (tr) 1998-02-27 1999-02-05 İzaşemi tedavisi için guanidin türevleri

Country Status (39)

Country Link
US (2) US6492401B1 (tr)
EP (2) EP1454902A1 (tr)
JP (2) JP2002504546A (tr)
KR (4) KR100449600B1 (tr)
CN (1) CN1289326A (tr)
AP (1) AP9901478A0 (tr)
AR (1) AR015526A1 (tr)
AT (1) ATE286034T1 (tr)
AU (1) AU739403B2 (tr)
BG (1) BG104803A (tr)
BR (1) BR9908332A (tr)
CA (1) CA2321642A1 (tr)
CO (1) CO4980897A1 (tr)
DE (1) DE69922930T2 (tr)
DK (1) DK1056729T3 (tr)
DZ (1) DZ2729A1 (tr)
EA (1) EA003603B1 (tr)
ES (1) ES2237080T3 (tr)
GT (1) GT199900022A (tr)
HR (2) HRP20000550A2 (tr)
HU (1) HUP0204418A3 (tr)
ID (1) ID25505A (tr)
IL (1) IL136588A0 (tr)
IS (1) IS5548A (tr)
NO (1) NO20004192L (tr)
NZ (1) NZ504769A (tr)
OA (1) OA11450A (tr)
PA (1) PA8468401A1 (tr)
PE (1) PE20000334A1 (tr)
PL (1) PL342444A1 (tr)
PT (1) PT1056729E (tr)
SI (1) SI1056729T1 (tr)
SK (1) SK12342000A3 (tr)
TN (1) TNSN99028A1 (tr)
TR (1) TR200002480T2 (tr)
TW (1) TWI226329B (tr)
WO (1) WO1999043663A1 (tr)
YU (1) YU46200A (tr)
ZA (1) ZA991578B (tr)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU739403B2 (en) * 1998-02-27 2001-10-11 Pfizer Products Inc. N-((substituted five-membered di- or triaza diunsaturated ring)carbonyl) guanidine derivatives for the treatment of ischemia
FR2795726A1 (fr) * 1999-06-30 2001-01-05 Aventis Cropscience Sa Nouveaux pyrazoles fongicides
US6441176B1 (en) 1999-10-29 2002-08-27 Pfizer Inc. Method for preparing sodium-hydrogen exchanger type 1 inhibitor
UA72002C2 (en) * 1999-10-29 2005-01-17 Pfizer Prod Inc Inhibitors crystals of sodium-hydrogen exchange of 1 type, a method for the preparation thereof (variants), a pharmaceuticalcomposition based thereon and a method for the reduction of tissue damage
YU54202A (sh) 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
HN2001000008A (es) 2000-01-21 2003-12-11 Inc Agouron Pharmaceuticals Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo
US6570013B2 (en) 2000-02-16 2003-05-27 Pfizer Inc Salts of zopolrestat
US6555569B2 (en) * 2000-03-07 2003-04-29 Pfizer Inc. Use of heteroaryl substituted N-(indole-2-carbonyl-) amides for treatment of infection
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
EP1274706A1 (en) 2000-04-18 2003-01-15 Agouron Pharmaceuticals, Inc. Pyrazoles for inhibiting protein kinases
TR200202439T2 (tr) * 2000-04-28 2003-02-21 Pfizer Products Inc. Sodyum hidrojen değiştirici tip 1 önleyici (NHE-1)
US6852733B2 (en) * 2000-04-28 2005-02-08 Pfizer Inc. Sodium-hydrogen exchanger type 1 inhibitor
IL144507A0 (en) * 2000-07-31 2002-05-23 Pfizer Prod Inc Use of glycogen phosphorylase inhibitors to inhibit tumor growth
EP1337508A1 (en) * 2000-11-28 2003-08-27 Pfizer Products Inc. Preparation of sodium-hydrogen exchanger type-1 inhibitors
IL147696A0 (en) * 2001-01-25 2002-08-14 Pfizer Prod Inc Combination therapy
US6423705B1 (en) 2001-01-25 2002-07-23 Pfizer Inc. Combination therapy
WO2002060892A1 (en) * 2001-01-31 2002-08-08 Pfizer Products Inc. Ethanolates of sodium-hydrogen exchanger type-1 inhibitor
WO2002098429A1 (en) * 2001-06-07 2002-12-12 Pfizer Products Inc. Ethanolamine, diethanolamine or triethanolamine salt of zopolrestat
AU2002352148A1 (en) * 2001-06-29 2003-03-03 Abbott Gmnh & Co. Kg Bis-aryl thiazole derivatives
JP2005511590A (ja) * 2001-11-02 2005-04-28 アベンティス・ファーマスーティカルズ・インコーポレイテツド アデノシンａ１／ａ２アゴニストおよびナトリウム水素交換体阻害剤を含む医薬組成物
CA2469305A1 (en) 2001-12-19 2003-06-26 Frank Robert Busch Methods for preparing sodium-hydrogen exchanger type-1 inhibitors
WO2003064409A1 (en) * 2002-01-30 2003-08-07 Pfizer Products Inc. Zoniporide mesylate pharmaceutical compositions and processes for improving solubility of zoniporide
CA2483927A1 (en) * 2002-05-02 2003-11-13 Pfizer Products Inc. Treatment of diabetes and diabetic complications with nhe-1 inhibitors
US7057046B2 (en) 2002-05-20 2006-06-06 Bristol-Myers Squibb Company Lactam glycogen phosphorylase inhibitors and method of use
FR2840302B1 (fr) * 2002-06-03 2004-07-16 Aventis Pharma Sa Derives d'isoindolones, procede de preparation et intermediaire de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant
FR2842525B1 (fr) 2002-07-16 2005-05-13 Aventis Pharma Sa Derives de 3-guanidinocarbonyl-1-heteroaryl-indole, procede de preparation a titre de medicaments et compositions pharmaceutiques les renfermant
FR2842526B1 (fr) 2002-07-16 2007-07-13 Aventis Pharma Sa Compositions pharmaceutiques contenant un derive de 3-guanidinocarbonyl-1-heteroaryl-indole, procede de preparation a titre de medicaments
FR2842524B1 (fr) * 2002-07-16 2005-04-22 Aventis Pharma Sa Compositions pharmaceutiques contenant un derive de 3-guanidinocarbonyl-1-heteroaryl-pyrrole, leur procede de preparation a titre de medicaments
DE60329030D1 (de) * 2002-12-04 2009-10-08 Ore Pharmaceuticals Inc Melanocortin-rezeptormodulatoren
ZA200505734B (en) * 2003-02-07 2006-12-27 Daiichi Seiyaku Co Pyrazole Derivative
TWI337078B (en) 2003-11-12 2011-02-11 Phenomix Corp Heterocyclic boronic acid compounds
US7317109B2 (en) 2003-11-12 2008-01-08 Phenomix Corporation Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US7576121B2 (en) 2003-11-12 2009-08-18 Phenomix Corporation Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
TW200526641A (en) * 2003-12-26 2005-08-16 Daiichi Seiyaku Co Amidopyrazole derivatives
WO2005079803A1 (en) * 2004-02-13 2005-09-01 Pfizer Products, Inc. Compounds for treatment of cardiovascular diseases
WO2006017292A1 (en) 2004-07-12 2006-02-16 Phenomix Corporation Constrained cyano compounds
WO2006053274A2 (en) 2004-11-15 2006-05-18 Bristol-Myers Squibb Company 2-amino-1-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
US7223786B2 (en) 2004-11-15 2007-05-29 Bristol-Myers Squibb Company 2-aminonaphthalene derivatives and related glycogen phosphorylase inhibitors
US7365061B2 (en) 2004-11-15 2008-04-29 Bristol-Myers Squibb Company 2-Amino-3-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
US7226942B2 (en) 2004-11-15 2007-06-05 Bristol-Myers Squibb Company 2-amino-4-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
PT1853296E (pt) * 2005-01-10 2012-09-26 Debiopharm Sa Utilização de um undecapeptídeo cíclico para a preparação de um medicamento para administração em situações de miocardia isquêmica
EP1879881A2 (en) 2005-04-14 2008-01-23 Bristol-Myers Squibb Company Inhibitors of 11-beta hydroxysteroid dehydrogenase type i
US7825139B2 (en) 2005-05-25 2010-11-02 Forest Laboratories Holdings Limited (BM) Compounds and methods for selective inhibition of dipeptidyl peptidase-IV
EP2046753A2 (en) 2006-07-06 2009-04-15 Brystol-Myers Squibb Company Pyridone/hydroxypyridine 11-beta hydroxysteroid dehydrogenase type i inhibitors
US7727978B2 (en) 2006-08-24 2010-06-01 Bristol-Myers Squibb Company Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors
JP2010524953A (ja) 2007-04-17 2010-07-22 ブリストル−マイヤーズ スクイブ カンパニー 縮合ヘテロ環１１−β−ヒドロキシステロイドデヒドロゲナーゼＩ型阻害剤
JP2010534722A (ja) 2007-07-27 2010-11-11 ブリストル−マイヤーズ スクイブ カンパニー 新規グルコキナーゼ活性化薬およびその使用方法
EP2294066B9 (en) 2008-04-28 2015-03-11 Janssen Pharmaceutica, N.V. Benzoimidazoles as prolyl hydroxylase inhibitors
US10517839B2 (en) 2008-06-09 2019-12-31 Cornell University Mast cell inhibition in diseases of the retina and vitreous
CN102224142B (zh) * 2008-11-21 2015-07-22 拉夸里亚创药株式会社 具有5-ht2b受体拮抗活性的新型吡唑-3-羧酰胺衍生物
WO2010094090A2 (en) * 2009-02-18 2010-08-26 Katholleke Universiteit Leuven Synucleinopathies
ES2559209T3 (es) 2010-04-14 2016-02-11 Bristol-Myers Squibb Company Nuevos activadores de la glucocinasa y métodos de uso de los mismos
CN102408385B (zh) * 2011-06-20 2014-06-18 雅本化学股份有限公司 一种2-取代-2h-1,2,3-三氮唑衍生物的制备方法
CN102408386B (zh) * 2011-07-27 2014-05-07 雅本化学股份有限公司 2,4-二取代-2h-1,2,3-三氮唑衍生物的制备方法
BR112014006940A2 (pt) 2011-09-23 2017-04-04 Bayer Ip Gmbh uso de derivados de ácido 1-fenilpirazol-3-carboxílico 4-substituído como agentes contra estresse abiótico em plantas
ES2574262T3 (es) 2011-10-25 2016-06-16 Janssen Pharmaceutica, N.V. Formulaciones de sal de meglumina de ácido 1-(5,6-dicloro-1h-benzo[d]imidazol-2-il)-1h-pirazol-4-carboxílico
EP2819675A4 (en) * 2012-02-27 2015-07-22 Essentialis Inc SALTS OF KALIUM ATP CHANNEL OPENERS AND USES THEREOF
EP3333163A4 (en) * 2015-08-06 2019-01-09 UBE Industries, Ltd. SUBSTITUTED GUANIDINE DERIVATIVE
WO2017057695A1 (ja) * 2015-09-30 2017-04-06 東レ株式会社 ジフェニルピラゾール誘導体及びその医薬用途
EP4029856B1 (en) * 2015-12-16 2024-03-27 Nippon Soda Co., Ltd. Arylazole compound and pest control agent
US10344002B2 (en) 2016-09-26 2019-07-09 Nusirt Sciences, Inc. Compositions and methods for treating metabolic disorders
CN108017584B (zh) * 2017-06-20 2021-03-23 南开大学 A3腺苷受体的小分子拮抗剂

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2104931B1 (tr) * 1970-09-08 1975-01-10 Ferlux
CA2121391A1 (en) 1993-04-28 1994-10-29 Atsuyuki Kojima Indoloylguanidine derivatives
IL109570A0 (en) 1993-05-17 1994-08-26 Fujisawa Pharmaceutical Co Guanidine derivatives, pharmaceutical compositions containing the same and processes for the preparation thereof
EP0639573A1 (de) * 1993-08-03 1995-02-22 Hoechst Aktiengesellschaft Benzokondensierte 5-Ringheterocyclen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, ihre Verwendung als Diagnostikum, sowie sie enthaltendes Medikament
US5852046A (en) 1993-08-03 1998-12-22 Hoechst Aktiengesellschaft Benzo-fused heterocyclic compounds having a 5-membered ring processes for their preparation their use as medicaments their use as diagnostic agents and medicaments containing them
DE4412334A1 (de) * 1994-04-11 1995-10-19 Hoechst Ag Substituierte N-Heteroaroylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
CA2160600A1 (en) * 1994-10-18 1996-04-19 Masahumi Kitano Indoloylguanidine derivatives
NZ314105A (en) 1996-02-02 1997-12-19 Sumitomo Pharma Guanidine derivative substituted with a substituted indole which is peri condensed with a heterocyclic ring
JPH09291076A (ja) 1996-04-24 1997-11-11 Sumitomo Pharmaceut Co Ltd 置換グアニジン誘導体およびその製法
AR009435A1 (es) * 1996-12-16 2000-04-12 Yamanouchi Pharma Co Ltd Derivado de guanaidina n-[carbonil(heteroaril-substituida de 5 miembros)], un inhibidor del intercambiador de na+/h+ que comprende dicho derivado y usosen la fabricacion de medicamentos.
AU739403B2 (en) * 1998-02-27 2001-10-11 Pfizer Products Inc. N-((substituted five-membered di- or triaza diunsaturated ring)carbonyl) guanidine derivatives for the treatment of ischemia

Also Published As

Publication number Publication date
CN1289326A (zh) 2001-03-28
DZ2729A1 (fr) 2005-03-01
CO4980897A1 (es) 2000-11-27
ZA991578B (en) 2000-08-28
NO20004192D0 (no) 2000-08-22
KR20030078886A (ko) 2003-10-08
KR100407903B1 (ko) 2003-12-01
KR20030009548A (ko) 2003-01-29
BR9908332A (pt) 2000-11-07
OA11450A (en) 2003-12-04
ATE286034T1 (de) 2005-01-15
US6974813B2 (en) 2005-12-13
EA200000789A1 (ru) 2001-02-26
PA8468401A1 (es) 2000-09-29
AP9901478A0 (en) 1999-03-31
DE69922930T2 (de) 2005-12-29
AU739403B2 (en) 2001-10-11
NZ504769A (en) 2005-04-29
EP1056729A1 (en) 2000-12-06
KR100449600B1 (ko) 2004-09-21
CA2321642A1 (en) 1999-09-02
WO1999043663A1 (en) 1999-09-02
SI1056729T1 (en) 2005-04-30
GT199900022A (es) 2000-08-15
TWI226329B (en) 2005-01-11
PT1056729E (pt) 2005-04-29
HUP0204418A3 (en) 2003-10-28
DK1056729T3 (da) 2005-04-11
HRP20000550A2 (en) 2001-02-28
IL136588A0 (en) 2001-06-14
EA003603B1 (ru) 2003-06-26
KR20010041397A (ko) 2001-05-15
NO20004192L (no) 2000-08-22
AR015526A1 (es) 2001-05-02
DE69922930D1 (de) 2005-02-03
BG104803A (bg) 2001-05-31
IS5548A (is) 2000-06-27
US6492401B1 (en) 2002-12-10
US20030149043A1 (en) 2003-08-07
PE20000334A1 (es) 2000-05-13
YU46200A (sh) 2003-02-28
KR20030083004A (ko) 2003-10-23
TNSN99028A1 (fr) 2005-11-10
JP2005041879A (ja) 2005-02-17
ES2237080T3 (es) 2005-07-16
AU2070699A (en) 1999-09-15
JP2002504546A (ja) 2002-02-12
SK12342000A3 (sk) 2001-03-12
EP1056729B1 (en) 2004-12-29
EP1454902A1 (en) 2004-09-08
HRP20010666A2 (en) 2001-10-31
PL342444A1 (en) 2001-06-04
HUP0204418A2 (hu) 2003-04-28
ID25505A (id) 2000-10-05

Similar Documents

Publication Publication Date Title
TR200002480T2 (tr) İzaşemi tedavisi için guanidin türevleri
TR200201505T2 (tr) Terapötik maddeler olarak pirazolopirimidinler
NO20003233D0 (no) 4-hydrokykinolin-3-karboksamider og hydraziner som antivirale midler
NO20005224L (no) BTK inhibitorer og fremgangsmåter for deres identifikasjon og anvendelse
TR200200843T2 (tr) İşemi'nin Tedavisi için olan bileşikler
NO20005237D0 (no) Heterocyklisk substituerte amider anvendt som calpain- inhibitorer
AR024138A1 (es) Inhibidores de la proliferacion celular
NO992492L (no) Benzamidoaldehyder og deres anvendelse som cystein-protease-inhibitorer
NO990405L (no) Substituerte N-(indol-2-karbonyl)-glycinamider og derivater som antidiabetiske midler
ES2170252T3 (es) Tetrahidroimidazopiridoindoldionas como inhibidores de cgmp especifico pde.
BR9811099A (pt) Inibidores de urocinase
ATE300541T1 (de) Pyrazolopyridinderivate
DE60121461D1 (de) Kondensierte pyridoindolderivate
ATE433963T1 (de) Fab-i inhibitoren
UY25712A1 (es) Benzamidas sustituidas y su aplicación en medicamentos
DK1097173T3 (da) Anvendelse af peptider af IL-2 og derivater deraf som terapeutiske midler
PA8586801A1 (es) Inhibidores de hiv-integrasa, composiciones farmaceuticas y metodos para su uso
DK1178726T3 (da) Vandig opløsning til konservering af væv og organer
DE60115466D1 (de) Wirkstoffvorläufer von imidazopyridin-derivaten
ATE333457T1 (de) Zyklische gmp-spezifische phosphodiesteraseinhibitoren
DK1109560T3 (da) Som AICARFT-inhibitorer anvendelige forbindelser
DK1015437T3 (da) Benzoxazin- og benzothiazin-derivater og deres anvendelse i lægemidler
DE60131968D1 (de) PYRANOÄ2,3-cÜIMIDAZOÄ1,2-aÜPYRIDIN-DERIVATE ZUR BEHANDLUNG VON GASTROINTESTINALEN ERKRANKUNGEN
ATE293111T1 (de) Kondensierte pyrazindionderivate als pde inhibitoren
SE9904128D0 (sv) Novel compounds